A5081145734- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Glioma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Prostate Cancer Treatment and Research
- Lung Cancer Research Studies
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Breast Implant and Reconstruction
Dana-Farber Cancer Institute
2016-2025
Harvard University
2012-2025
Brigham and Women's Hospital
2003-2024
Dana-Farber Brigham Cancer Center
2012-2023
Boston University
2022-2023
Columbus Oncology and Hematology Associates
2020
University of Florida
2020
CancerCare
2017-2019
Dana-Farber/Harvard Cancer Center
2017-2019
Broad Institute
2019
This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients metastatic breast cancer previously treated an anthracycline taxane.Patients were randomly assigned receive (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone combination bevacizumab (15 mg/kg) 1. The primary end point was progression-free survival (PFS), as determined by independent review...
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these have been ineligible the pivotal trials adjuvant trastuzumab.We performed an uncontrolled, single-group, multicenter, investigator-initiated study paclitaxel and trastuzumab in 406 tumors measuring up to 3 cm greatest dimension. Patients received weekly 12 weeks, followed by 9 months monotherapy. The primary end point...
This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.Heavily pretreated metastatic cancers were randomly assigned to one five dose cohorts administered once daily. Pharmacokinetic samples obtained on days 1 20. Clinical response was every 8 weeks.Sixty-seven tumors treated lapatinib. The most frequently...
This randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen.Patients (n = 449) were randomly assigned to receive either 100 mg/m2 225) or 175 224) on day 1, every 21 days until tumor progression, unacceptable toxicity, withdrawal of consent.In the intent-to-treat population, both median overall survival (OS, 15.4 v 12.7 months;...
This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies.Heavily pretreated metastatic cancers overexpressing ErbB2 expressing were randomly assigned one five dose cohorts (GW572016) administered orally once daily continuously. The growth and survival assessed biopsies obtained before after 21 days therapy. Clinical response determined at 8 weeks.Sequential from...
The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. primary analysis the demonstrated a 3-year disease-free survival (DFS) 98.7%. In this planned secondary analysis, we report longer-term outcomes exploratory results characterize biology HER2-positive tumors genetic factors that may predispose paclitaxel-induced peripheral neuropathy (TIPN).In phase II study, cancer 3 cm...
The androgen receptor is a tumour suppressor in oestrogen receptor-positive breast cancer. activity and safety of enobosarm, an oral selective modulator, was evaluated women with (ER)-positive, HER2-negative, (AR)-positive disease.
Trastuzumab-based therapy improves survival for women with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined vinorelbine, assess cardiac surveillance algorithms tumor markers as prognostic tools.Patients HER2-positive (immunohistochemistry [IHC] 3+-positive or fluorescence in situ hybridization [FISH]-positive) metastatic cancer received first-line chemotherapy...
1019 Background: Veliparib (ABT-888) is a novel oral inhibitor of Poly (ADP-Ribose) Polymerase (PARP) 1 and 2. temozolomide (TMZ) are synergistic in breast cancer xenograft models. TMZ has minimal activity likely due to robust repair methylated DNA adducts by the base excision (BER) pathway MGMT. We hypothesized that combining veliparib with would be active metastatic (MBC). Methods: conducted single arm phase II trial 41 MBC patients (pts). Eligibility included measurable MBC, >1 prior...
Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated safety efficacy of ruxolitinib patients with metastatic This was non-randomized phase II study enrolling refractory, triple-negative The primary endpoint objective response by RECIST 1.1. designed to enroll whose archival tumor tissue pSTAT3-positive (T-score >5) central immunohistochemistry. pSTAT3...
<h3>Importance</h3> Prior studies have shown that only a small proportion of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC) experience benefit from programmed cell death 1 (PD-1)/programmed ligand (PD-L1) inhibitors given as monotherapy. There are data suggesting activity may be greater combination strategies. <h3>Objective</h3> To compare the efficacy eribulin plus pembrolizumab vs alone in HR-positive,<i>ERBB2 </i>(formerly<i>HER2</i>)–negative MBC. <h3>Design,...
National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary Conference of Morgan Welch Inflammatory Breast Cancer Research Program The University Texas MD Anderson Center Houston Texas. A consensus on clinical management patients with was discussed, summarized, subsequently reviewed. All participants conference (patients, advocates, researchers, trainees, clinicians) were queried using MDRing...
Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. conducted single arm phase II biomarker study that enrolled measurable Patients received cabozantinib (60 mg daily) on 3-week cycle were restaged after 6 weeks then every 9 weeks. The primary endpoint was objective rate. Predefined secondary endpoints included...
Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with poor prognosis and limited treatment options. We present single arm Phase II study of 18 patients LMD receiving combined ipilimumab nivolumab until progression or unacceptable toxicity (NCT02939300). The primary end point overall survival at 3 months (OS3). Secondary points include toxicity, cumulative time-to-progression months, progression-free survival. A Simon two-stage design used to compare null...
Abstract Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance treatment. In cancer, CD44+CD24− cells possess stem cell-like features contribute progression, we previously described CD44+CD24−pSTAT3+ cell subpopulation that dependent on JAK2/STAT3 signaling. Here report are the most frequent type in IBC commonly pSTAT3+. Combination inhibition paclitaxel decreased xenograft growth more than either agent...
Abstract The landscape of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) resistance is still being elucidated and the optimal subsequent therapy to overcome remains uncertain. Here we present final results a phase Ib/IIa, open-label trial (NCT02871791) exemestane plus everolimus palbociclib for CDK4/6i-resistant metastatic breast cancer. primary objective Ib was evaluate safety tolerability determine maximum tolerated dose/recommended II dose (100 mg palbociclib, 5 everolimus, 25...
PURPOSE Thrombocytopenia may compromise cancer treatment, causing chemotherapy dose reductions, schedule alterations, or the need for platelet transfusions. We evaluated efficacy and safety of recombinant human interleukin-11 (rhIL-11; Neumega, Genetics Institute, Inc, Cambridge, MA), a novel thrombopoietic growth factor, in reducing transfusions patients who undergo dose-intensive chemotherapy. PATIENTS AND METHODS Women with advanced breast received cyclophosphamide (3,200 mg/m2)...
Abstract Purpose: The purpose of our study was to review and determine the cardiovascular safety profile combretastatin A4 phosphate (CA4P) in a Phase I 25 patients with advanced solid tumors. Experimental Design: CA4P administered dose-escalating fashion starting at 18 mg/m2 i.v. every 21 days, maximal dosage 90 mg/m2. Continuous evaluation included bedside blood pressure pulse monitoring, 12-lead electrocardiogram (ECG) fixed time points for measured QT interval determination,...
The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in vitro. This phase I study assessed the safety, clinical feasibility, optimally tolerated regimen (OTR), pharmacokinetics (PK), preliminary activity this patients with advanced cancer.Cohorts three were treated escalating doses (750 1,500 mg) administered once daily (continuous) (4 mg/kg loading dose then 2 weekly) determine OTR. Once OTR...
Taxanes have effects on angiogenesis causing difficulties in separating biological of chemotherapy from those due to inhibitors. This randomized phase II trial was designed evaluate the additional biomarker effect when bevacizumab is added docetaxel.Patients with inoperable breast cancer were either 2 cycles preoperative docetaxel (D) 35 mg/m(2) i.v. weekly for 6 weeks, followed by a 2-week break; or 10 mg/kg every other week total 16 weeks (DB). Plasma and serum markers endothelial damage,...